Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Jiangsu Zhongbang Pharmaceutical Co, Ltd

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 12-Ethoxy-1-[[2

    02 12-n-Propyl-4-Methyl-6-(1-Methyl Benzimidazole-2-yl)Benzimidazole

    03 14-Chloromethyl-5-methyl-[1,3]dioxol-2-one

    04 14-Methyl-2-n-Propyl-1H-Benzimidazole-6-Carboxylic Acid

    05 1Ethyl4-(1-Hydroxy-1-Methylethyl)-2-Propyl-Imidazole-5-Carboxylate

    06 1Methyl 4

    07 1Methyl 4’-Bromomethyl Biphenyl-2-Carboxylate

    08 1TritylCandesartan Cilexetil

    09 1TritylOlmesartanMedoxomil

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    PharmaCompass
    ListList of Suppliers
    Contact SupplierContact Supplier
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us
    Contact Supplier
    • Audit Compliance
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    2-Ethoxy-1-[[2

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    1397836-41-7
    Azilsartan
    Jiangsu Zhongbang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Red Sun Group. Company ha...
    Jiangsu Zhongbang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Red Sun Group. Company has been founded since 2001 and occupied 100,000m2. Company has 80 million RMB registered capital and plan to have a total investment of 200 million RMB. Company has 168 employees at present, in which there are 34 employees with Bachelor’s Degree or above, 12 employees with Master’s Degree or above, each kind of professional talents have occupied over 60% of the total employees. Company has got China GMP certificate since 2006 and currently has one GMP plant for API and one GMP plant for solid finished products. There are two production lines in API GMP plants with annual capacity of 50 tons API. There are equipment for tablets, capsules and granules in solid finished products. Company has set up qualified documentation systems according to China GMP and Europe and USA C-GMP. Company has the plan to pass COS and FDA authentication both around 2014. Company also pays serious attention on public welfare and concerns on green energy conservation and environmental protection undertaking.
    blank

    01

    2-Ethoxy-1-[[2

    China
    2024 ACI Convention
    Not Confirmed
    arrow

    2-Ethoxy-1-[[2

    China
    2024 ACI Convention
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Jiangsu Zhongbang Pharmaceutical Co, Ltd

    2-Ethoxy-1-[[2

    CAS Number : 1397836-41-7

    End Use API : Azilsartan

    About the Company : Jiangsu Zhongbang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Red Sun Group. Company has been founded since...

    blank

    Intermediate Web Link

    Market Place

    Contact Supplier
    • Audit Compliance
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    2-n-Propyl-4-Methyl-6-(1-Methyl Benzimidazole-2-yl)Benzimidazo...

    Intermediate Web Link

    Market Place

    152628-02-9
    Telmisartan
    Jiangsu Zhongbang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Red Sun Group. Company ha...
    Jiangsu Zhongbang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Red Sun Group. Company has been founded since 2001 and occupied 100,000m2. Company has 80 million RMB registered capital and plan to have a total investment of 200 million RMB. Company has 168 employees at present, in which there are 34 employees with Bachelor’s Degree or above, 12 employees with Master’s Degree or above, each kind of professional talents have occupied over 60% of the total employees. Company has got China GMP certificate since 2006 and currently has one GMP plant for API and one GMP plant for solid finished products. There are two production lines in API GMP plants with annual capacity of 50 tons API. There are equipment for tablets, capsules and granules in solid finished products. Company has set up qualified documentation systems according to China GMP and Europe and USA C-GMP. Company has the plan to pass COS and FDA authentication both around 2014. Company also pays serious attention on public welfare and concerns on green energy conservation and environmental protection undertaking.
    blank

    02

    2-n-Propyl-4-Methyl-6-(1-Methyl Benzimidazole-2-yl)Benzimidazole

    China
    2024 ACI Convention
    Not Confirmed
    arrow
    Contact Supplier
    • Audit Compliance
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    4-Chloromethyl-5-methyl-[1,3]dioxol-2-one

    Intermediate Web Link

    Market Place

    80841-78-7
    Olmesartan Medoxomil
    Jiangsu Zhongbang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Red Sun Group. Company ha...
    Jiangsu Zhongbang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Red Sun Group. Company has been founded since 2001 and occupied 100,000m2. Company has 80 million RMB registered capital and plan to have a total investment of 200 million RMB. Company has 168 employees at present, in which there are 34 employees with Bachelor’s Degree or above, 12 employees with Master’s Degree or above, each kind of professional talents have occupied over 60% of the total employees. Company has got China GMP certificate since 2006 and currently has one GMP plant for API and one GMP plant for solid finished products. There are two production lines in API GMP plants with annual capacity of 50 tons API. There are equipment for tablets, capsules and granules in solid finished products. Company has set up qualified documentation systems according to China GMP and Europe and USA C-GMP. Company has the plan to pass COS and FDA authentication both around 2014. Company also pays serious attention on public welfare and concerns on green energy conservation and environmental protection undertaking.
    blank

    03

    4-Chloromethyl-5-methyl-[1,3]dioxol-2-one

    China
    2024 ACI Convention
    Not Confirmed
    arrow
    Contact Supplier
    • Audit Compliance
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    4-Methyl-2-n-Propyl-1H-Benzimidazole-6-Carboxylic Acid

    Intermediate Web Link

    Market Place

    152628-03-0
    Telmisartan
    Jiangsu Zhongbang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Red Sun Group. Company ha...
    Jiangsu Zhongbang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Red Sun Group. Company has been founded since 2001 and occupied 100,000m2. Company has 80 million RMB registered capital and plan to have a total investment of 200 million RMB. Company has 168 employees at present, in which there are 34 employees with Bachelor’s Degree or above, 12 employees with Master’s Degree or above, each kind of professional talents have occupied over 60% of the total employees. Company has got China GMP certificate since 2006 and currently has one GMP plant for API and one GMP plant for solid finished products. There are two production lines in API GMP plants with annual capacity of 50 tons API. There are equipment for tablets, capsules and granules in solid finished products. Company has set up qualified documentation systems according to China GMP and Europe and USA C-GMP. Company has the plan to pass COS and FDA authentication both around 2014. Company also pays serious attention on public welfare and concerns on green energy conservation and environmental protection undertaking.
    blank

    04

    4-Methyl-2-n-Propyl-1H-Benzimidazole-6-Carboxylic Acid

    China
    2024 ACI Convention
    Not Confirmed
    arrow
    Contact Supplier
    • Audit Compliance
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Ethyl4-(1-Hydroxy-1-Methylethyl)-2-Propyl-Imidazole-5-Carboxyl...

    Intermediate Web Link

    Market Place

    144689-93-0
    Olmesartan Medoxomil
    Jiangsu Zhongbang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Red Sun Group. Company ha...
    Jiangsu Zhongbang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Red Sun Group. Company has been founded since 2001 and occupied 100,000m2. Company has 80 million RMB registered capital and plan to have a total investment of 200 million RMB. Company has 168 employees at present, in which there are 34 employees with Bachelor’s Degree or above, 12 employees with Master’s Degree or above, each kind of professional talents have occupied over 60% of the total employees. Company has got China GMP certificate since 2006 and currently has one GMP plant for API and one GMP plant for solid finished products. There are two production lines in API GMP plants with annual capacity of 50 tons API. There are equipment for tablets, capsules and granules in solid finished products. Company has set up qualified documentation systems according to China GMP and Europe and USA C-GMP. Company has the plan to pass COS and FDA authentication both around 2014. Company also pays serious attention on public welfare and concerns on green energy conservation and environmental protection undertaking.
    blank

    05

    Ethyl4-(1-Hydroxy-1-Methylethyl)-2-Propyl-Imidazole-5-Carboxylate

    China
    2024 ACI Convention
    Not Confirmed
    arrow
    Contact Supplier
    • Audit Compliance
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Methyl 4

    Intermediate Web Link

    Market Place

    114772-34-8
    Telmisartan
    Jiangsu Zhongbang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Red Sun Group. Company ha...
    Jiangsu Zhongbang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Red Sun Group. Company has been founded since 2001 and occupied 100,000m2. Company has 80 million RMB registered capital and plan to have a total investment of 200 million RMB. Company has 168 employees at present, in which there are 34 employees with Bachelor’s Degree or above, 12 employees with Master’s Degree or above, each kind of professional talents have occupied over 60% of the total employees. Company has got China GMP certificate since 2006 and currently has one GMP plant for API and one GMP plant for solid finished products. There are two production lines in API GMP plants with annual capacity of 50 tons API. There are equipment for tablets, capsules and granules in solid finished products. Company has set up qualified documentation systems according to China GMP and Europe and USA C-GMP. Company has the plan to pass COS and FDA authentication both around 2014. Company also pays serious attention on public welfare and concerns on green energy conservation and environmental protection undertaking.
    blank

    06

    Methyl 4

    China
    2024 ACI Convention
    Not Confirmed
    arrow

    Methyl 4

    China
    2024 ACI Convention
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Jiangsu Zhongbang Pharmaceutical Co, Ltd

    Methyl 4

    CAS Number : 114772-34-8

    End Use API : Telmisartan

    About the Company : Jiangsu Zhongbang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Red Sun Group. Company has been founded since...

    blank

    Intermediate Web Link

    Market Place

    Contact Supplier
    • Audit Compliance
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Methyl 4’-Bromomethyl Biphenyl-2-Carboxylate

    Intermediate Web Link

    Market Place

    114772-38-2
    Telmisartan
    Jiangsu Zhongbang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Red Sun Group. Company ha...
    Jiangsu Zhongbang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Red Sun Group. Company has been founded since 2001 and occupied 100,000m2. Company has 80 million RMB registered capital and plan to have a total investment of 200 million RMB. Company has 168 employees at present, in which there are 34 employees with Bachelor’s Degree or above, 12 employees with Master’s Degree or above, each kind of professional talents have occupied over 60% of the total employees. Company has got China GMP certificate since 2006 and currently has one GMP plant for API and one GMP plant for solid finished products. There are two production lines in API GMP plants with annual capacity of 50 tons API. There are equipment for tablets, capsules and granules in solid finished products. Company has set up qualified documentation systems according to China GMP and Europe and USA C-GMP. Company has the plan to pass COS and FDA authentication both around 2014. Company also pays serious attention on public welfare and concerns on green energy conservation and environmental protection undertaking.
    blank

    07

    Methyl 4’-Bromomethyl Biphenyl-2-Carboxylate

    China
    2024 ACI Convention
    Not Confirmed
    arrow
    Contact Supplier
    • Audit Compliance
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    TritylCandesartan Cilexetil

    Intermediate Web Link

    Market Place

    170791-09-0
    Candesartan Cilexetil
    Jiangsu Zhongbang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Red Sun Group. Company ha...
    Jiangsu Zhongbang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Red Sun Group. Company has been founded since 2001 and occupied 100,000m2. Company has 80 million RMB registered capital and plan to have a total investment of 200 million RMB. Company has 168 employees at present, in which there are 34 employees with Bachelor’s Degree or above, 12 employees with Master’s Degree or above, each kind of professional talents have occupied over 60% of the total employees. Company has got China GMP certificate since 2006 and currently has one GMP plant for API and one GMP plant for solid finished products. There are two production lines in API GMP plants with annual capacity of 50 tons API. There are equipment for tablets, capsules and granules in solid finished products. Company has set up qualified documentation systems according to China GMP and Europe and USA C-GMP. Company has the plan to pass COS and FDA authentication both around 2014. Company also pays serious attention on public welfare and concerns on green energy conservation and environmental protection undertaking.
    blank

    08

    TritylCandesartan Cilexetil

    China
    2024 ACI Convention
    Not Confirmed
    arrow

    TritylCandesartan Cilexetil

    China
    2024 ACI Convention
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Jiangsu Zhongbang Pharmaceutical Co, Ltd

    TritylCandesartan Cilexetil

    CAS Number : 170791-09-0

    End Use API : Candesartan Cilexetil

    About the Company : Jiangsu Zhongbang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Red Sun Group. Company has been founded since...

    blank

    Intermediate Web Link

    Market Place

    Contact Supplier
    • Audit Compliance
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    TritylOlmesartanMedoxomil

    Intermediate Web Link

    Market Place

    144690-92-6
    Olmesartan Medoxomil
    Jiangsu Zhongbang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Red Sun Group. Company ha...
    Jiangsu Zhongbang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Red Sun Group. Company has been founded since 2001 and occupied 100,000m2. Company has 80 million RMB registered capital and plan to have a total investment of 200 million RMB. Company has 168 employees at present, in which there are 34 employees with Bachelor’s Degree or above, 12 employees with Master’s Degree or above, each kind of professional talents have occupied over 60% of the total employees. Company has got China GMP certificate since 2006 and currently has one GMP plant for API and one GMP plant for solid finished products. There are two production lines in API GMP plants with annual capacity of 50 tons API. There are equipment for tablets, capsules and granules in solid finished products. Company has set up qualified documentation systems according to China GMP and Europe and USA C-GMP. Company has the plan to pass COS and FDA authentication both around 2014. Company also pays serious attention on public welfare and concerns on green energy conservation and environmental protection undertaking.
    blank

    09

    TritylOlmesartanMedoxomil

    China
    2024 ACI Convention
    Not Confirmed
    arrow

    TritylOlmesartanMedoxomil

    China
    2024 ACI Convention
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Jiangsu Zhongbang Pharmaceutical Co, Ltd

    TritylOlmesartanMedoxomil

    CAS Number : 144690-92-6

    End Use API : Olmesartan Medoxomil

    About the Company : Jiangsu Zhongbang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Red Sun Group. Company has been founded since...

    blank

    Intermediate Web Link

    Market Place

    Contact Jiangsu Zhongbang Pharmaceutical Co, Ltd and get a quotation

    Jiangsu Zhongbang Pharmaceutical Co, Ltd is a supplier offers 14 products (APIs, Excipients or Intermediates).

    Find a price of Telmisartan bulk with CEP, JDMF offered by Jiangsu Zhongbang Pharmaceutical Co, Ltd

    Find a price of Esomeprazole Magnesium bulk with CEP offered by Jiangsu Zhongbang Pharmaceutical Co, Ltd

    Find a price of Azilsartan bulk offered by Jiangsu Zhongbang Pharmaceutical Co, Ltd

    Find a price of Candesartan Cilexetil bulk offered by Jiangsu Zhongbang Pharmaceutical Co, Ltd

    Find a price of Efavirenz bulk offered by Jiangsu Zhongbang Pharmaceutical Co, Ltd

    Find a price of Esomeprazole Sodium bulk offered by Jiangsu Zhongbang Pharmaceutical Co, Ltd

    Find a price of Lansoprazole bulk offered by Jiangsu Zhongbang Pharmaceutical Co, Ltd

    Find a price of Nevirapine bulk offered by Jiangsu Zhongbang Pharmaceutical Co, Ltd

    Find a price of Olmesartan Medoxomil bulk offered by Jiangsu Zhongbang Pharmaceutical Co, Ltd

    Find a price of Omeprazole bulk offered by Jiangsu Zhongbang Pharmaceutical Co, Ltd

    Find a price of Rivaroxaban bulk offered by Jiangsu Zhongbang Pharmaceutical Co, Ltd

    Find a price of Sacubitril-Valsartan bulk offered by Jiangsu Zhongbang Pharmaceutical Co, Ltd

    Find a price of Telmisartan bulk offered by Jiangsu Zhongbang Pharmaceutical Co, Ltd

    Find a price of Valsartan bulk offered by Jiangsu Zhongbang Pharmaceutical Co, Ltd